Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$38.49 USD

38.49
428,011

+0.83 (2.20%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $38.45 -0.04 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

Here's Why You Must Add Surmodics (SRDX) to Your Portfolio

Surmodics' (SRDX) efforts to improve research and development stature bode well.

    SYK or SRDX: Which is a Better Medical Product Stock?

    Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.

      Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?

      Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.

        4 Medical Device Stocks with Solid Potential to Buy Now

        The Medical Device tax suspension spells good times for MedTech bigwigs.

          Surmodics (SRDX) Hits Fresh Highs: Is There Still Room to Run?

          Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.

            Surmodics (SRDX) Gains From Consistent Efforts to Boost R&D

            Surmodics' (SRDX) consistent focus on research and development activities has been driving growth. The company is expected to make continued progress throughout the remainder of fiscal 2018.

              Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM

              Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM

                Baxter International (BAX) Hits a 52-Week High, Can the Run Continue?

                Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.

                  Tirthankar Chakraborty headshot

                  5 Top Efficient Stocks to Keep on Your Radar

                  We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

                    Surmodics (SRDX) Hits a 52-Week High, Can the Run Continue?

                    Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.

                      Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View

                      Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                        SRDX or HAE: Which is a Better Medical Product Stock?

                        Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.

                          Here's Why You Should Invest in Surmodics (SRDX) Right Now

                          Surmodics (SRDX) continues to benefit from solid growth in the In Vitro Diagnostics (IVD) segment.

                            Can The Uptrend Continue for Surmodics (SRDX)?

                            Investors certainly have to be happy with Surmodics, Inc. (SRDX) and its short term performance

                              Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

                              Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

                                Tirthankar Chakraborty headshot

                                5 Top-Ranked Efficient Stocks to Boost Your Portfolio

                                A company with a favorable efficiency level will provide impressive returns irrespective of market conditions

                                  3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax

                                  Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.

                                    Abbott to Strengthen Vascular Care Arm With Surmodics Deal

                                    Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.

                                      Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid

                                      Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.

                                        Surmodics (SRDX) Poised on Core Business Amid Forex Woes

                                        Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.

                                          New Strong Sell Stocks for January 8th

                                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                            SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates

                                            SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.

                                              Surmodics Receives FDA's Approval for PTA Balloon Catheter

                                              Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

                                                Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet

                                                Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.

                                                  Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3

                                                  Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.